Japan-Flag  Korea-Flag  China-Simplified-Flag  China-Traditional-Flag 

Conference Menu

Day 1
Day 2
Short Course
View Brochure
Attendee List
Hotel & Travel
Exhibitor Kit
View Exhibitors/Floor Plan
Exhibit Contract
Sponsor & Exhibits
Press Pass 
Request Brochure

Premier Sponsor:


Corporate Sponsor:

Schrodinger logo

Corporate Support Sponsor:


Media Sponsor:


Sponsoring Society:


Lead Sponsoring Publications:

Clinical Informatics News


Insight Pharma Reports



Science AAAS 

Scientific Computing Logo Small

The Scientist

Web Partners:


Fierce Biotech IT



This event only comes once a year...don't miss out!
Register today!  

Experimental methods such as X-ray crystallography, NMR, and computational chemistry techniques have led to a better understanding and larger knowledge base of 3-dimensional structures and binding events, encouraging rapid development of structure-based drug design. Cambridge Healthtech Institute’s Fourteenth Annual Structure-Based Drug Design event will showcase informative, high-quality case studies, innovative techniques, and strategies to move from computation to experiment, and finally, to drug. Top scientists from pharma and biotech will address how they are hitting epigenetic targets, provide updates on the newest wave of GPCRs and other membrane proteins, and discuss the latest in fragment-based drug design. Attendees will return to their organizations with fresh perspectives and new ideas to maximize productivity and increase successes in drug discovery.

Keynote Speaker 

Chas BountraChas Bountra, Ph.D.

Professor, Translational Medicine, Department of Clinical Medicine; Associate Head, Medical Sciences; Chief Scientist, Structural Genomics Consortium, University of Oxford


What’s New This Year:

  • Coverage of novel targets and compounds including macrocycles, epigenetic targets, and BACE inhibitors
  • Case studies and experimental follow-up - see how Constellation, Heptares, AstraZeneca, and others are leading the SBDD charge
  • Expanded sessions on GPCR design and drug discovery
  • Showcase of different approaches for working with the similar targets

Hear up-to-the-minute case studies from:

  • Arena Pharmaceuticals
  • Astex
  • AstraZeneca
  • Bristol-Myers Squibb
  • Carmolex
  • Carmot Therapeutics
  • Constellation Pharmaceuticals
  • Genentech
  • Heptares Therapeutics UK
  • Merck
  • Novartis
  • Structural Genomics Consortium
  • Takeda
  • Vernalis, Ltd.

  Pre-Conference Dinner Short Course* 

Tuesday, May 20 | 6:00-9:00 pm

Structure- and dynamics-based design strategies 

This course will reveal design strategies that led to drugs currently in the clinic and on the market. An emphasis will be made on the exploitation of the bioactive ligand conformations using combinations of NMR, X-ray, calculations and SAR. Rational design and the implications of other properties will be addressed which include atropisomer chirality, drug self-aggregation and ADMET.

Steven LaPlante, Ph.D., Founder & CEO, NMX Research & Solutions; Adjunct Professor, Institut National de la Recherche Scientifique (INRS)

Chris Williams, Ph.D., Principal Scientist, Chemical Computing Group

Detailed Agenda:
6:00 Dinner Served

6:15 Strategies for Drug Design Starting from Peptides, HTS Hits and Small-Molecule Fragments

Steven LaPlante, Ph.D., Founder & CEO, NMX Research & Solutions; Adjunct Professor, Institut National de la Recherche Scientifique (INRS

7:15 Coffee Break

7:45 Designing Inhibitors with MOE Structure-Based Drug Design Tools

Chris Williams, Ph.D., Principal Scientist, Chemical Computing Group

8:45 Q&A with Speakers

9:00 Close of Course

*Separate Registration Required